Pub Date : 2024-07-09DOI: 10.1016/j.pharma.2024.07.002
Céline Couteau, Marie Orieux, Christian Lainé, Rachel Bocher, Laurence Coiffard
Objectives: Socio-aesthetics is a practice born in psychiatric departments but has since developed particularly in the field of oncology. For our part, since January 2018, we have initiated an experiment of this type at the Espace Unit of the CHU in Nantes, a unit that takes care of young patients who find themselves in a situation of crisis and endangerment of themselves.
Methods: The qualitative evaluation of the interest of a socio-aesthetic mediation (relaxation modelling, facial care, make-up) with young patients was carried out by a collection of their feelings.
Results: Youth who expressed an overall judgment of socio-esthetic mediation appreciated it in 61% of cases. They express their satisfaction with words such as "I liked", "I loved", "I'm happy", "it was too good", "super good" or "great".
Conclusion: This successful socio-aesthetic therapy practice experiment will continue with a quantitative analysis to demonstrate the relevance of this type of service to psychiatric patients.
{"title":"Feedback on a socio-aesthetic program for the benefit of young patients with self-endangerment.","authors":"Céline Couteau, Marie Orieux, Christian Lainé, Rachel Bocher, Laurence Coiffard","doi":"10.1016/j.pharma.2024.07.002","DOIUrl":"10.1016/j.pharma.2024.07.002","url":null,"abstract":"<p><strong>Objectives: </strong>Socio-aesthetics is a practice born in psychiatric departments but has since developed particularly in the field of oncology. For our part, since January 2018, we have initiated an experiment of this type at the Espace Unit of the CHU in Nantes, a unit that takes care of young patients who find themselves in a situation of crisis and endangerment of themselves.</p><p><strong>Methods: </strong>The qualitative evaluation of the interest of a socio-aesthetic mediation (relaxation modelling, facial care, make-up) with young patients was carried out by a collection of their feelings.</p><p><strong>Results: </strong>Youth who expressed an overall judgment of socio-esthetic mediation appreciated it in 61% of cases. They express their satisfaction with words such as \"I liked\", \"I loved\", \"I'm happy\", \"it was too good\", \"super good\" or \"great\".</p><p><strong>Conclusion: </strong>This successful socio-aesthetic therapy practice experiment will continue with a quantitative analysis to demonstrate the relevance of this type of service to psychiatric patients.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-28DOI: 10.1016/j.pharma.2024.06.006
Himani Acharya, Rajendra Kotadiya
Objective: The present work represents a reverse-phase high-performance liquid chromatography method in addition to stability studies for sequential estimation of remogliflozin etabonate, vildagliptin, and metformin HCl in tablet formulation.
Method: The mentioned method utilizes a Phenomenex Luna C18 column (250×4.6mm, 5μm). It consists of a column oven's temperature of 35°C. Mobile phase includes a mixture of 50% phosphate buffer (pH - 6.8) and 50% acetonitrile along with a flow rate of 0.8mL/min and 20minutes of run time. The injection volume was 20μL; 217nm is a detection wavelength, and a PDA detector is used for detection.
Results: The suggested technique was proven and validated per the ICH Q2 (R1) guideline. The combination was put under stress conditions that included acid, base, thermal, photolytic, and oxidative degradation. The combination was considerably degraded under oxidative, acidic, and basic circumstances for deterioration, and the degradation results were accurately identified from the observed peaks, demonstrating the method's effectiveness in detecting stability.
Conclusion: The technique was quick, precise, sensitive, and accurate; as a result, it may be used in quality control laboratories and the pharmaceutical industry for routine quality monitoring of tablets containing all three medications.
{"title":"Stability-indicating HPLC for remogliflozin, vildagliptin, and metformin: Method development, validation, and greenness.","authors":"Himani Acharya, Rajendra Kotadiya","doi":"10.1016/j.pharma.2024.06.006","DOIUrl":"10.1016/j.pharma.2024.06.006","url":null,"abstract":"<p><strong>Objective: </strong>The present work represents a reverse-phase high-performance liquid chromatography method in addition to stability studies for sequential estimation of remogliflozin etabonate, vildagliptin, and metformin HCl in tablet formulation.</p><p><strong>Method: </strong>The mentioned method utilizes a Phenomenex Luna C18 column (250×4.6mm, 5μm). It consists of a column oven's temperature of 35°C. Mobile phase includes a mixture of 50% phosphate buffer (pH - 6.8) and 50% acetonitrile along with a flow rate of 0.8mL/min and 20minutes of run time. The injection volume was 20μL; 217nm is a detection wavelength, and a PDA detector is used for detection.</p><p><strong>Results: </strong>The suggested technique was proven and validated per the ICH Q2 (R1) guideline. The combination was put under stress conditions that included acid, base, thermal, photolytic, and oxidative degradation. The combination was considerably degraded under oxidative, acidic, and basic circumstances for deterioration, and the degradation results were accurately identified from the observed peaks, demonstrating the method's effectiveness in detecting stability.</p><p><strong>Conclusion: </strong>The technique was quick, precise, sensitive, and accurate; as a result, it may be used in quality control laboratories and the pharmaceutical industry for routine quality monitoring of tablets containing all three medications.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141465828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-28DOI: 10.1016/j.pharma.2024.06.003
Rohit Chavhan
Introduction: Nanosuspensions have emerged as a promising avenue in pharmaceutical innovation, particularly for enhancing the bioavailability of poorly soluble medications. This article explores the transformative potential of nanosuspensions, emphasizing the critical role of particle size reduction through nanonization techniques. With conventional approaches often falling short in addressing the bioavailability challenges of hydrophobic drugs, nanosuspensions offer multifaceted applications and distinctive advantages in drug delivery.
Methods: The study delves into various nanosuspension preparation techniques, including high-pressure homogenization, media milling, emulsification-solvent evaporation, precipitation, and supercritical fluid processes. Each method brings unique advantages and limitations, contributing to the expanding repertoire of nanosuspension formulation methods. The article emphasizes the necessity for meticulous planning, evaluation, and ongoing research across different drugs to optimize their use effectively.
Results: Nanosuspensions exhibit versatility in administration routes, spanning parenteral, peroral, ocular, and pulmonary pathways, making them applicable across diverse dosage forms. Current efforts are directed towards furthering their application in site-specific medication administration, indicating their potential in tailored therapeutic strategies. Nanosuspensions offer a promising solution for enhancing drug solubility and bioavailability, addressing the persistent challenge of poor solubility in pharmaceutical compounds.
Discussion: The significance of careful formulation and stabilization using polymers and surfactants is underscored, ensuring the efficacy and safety of nanosuspensions. By discussing the benefits, drawbacks, and nuances of each preparation technique, the article aims to simplify future research endeavors in the field of nanosuspensions. Additionally, a comprehensive overview of nanosuspensions, including their preparation methods, benefits, characterization, patents, marketed products, and intended uses, sheds light on this evolving domain in pharmaceutical sciences.
Conclusion: Nanosuspensions represent a promising approach for overcoming bioavailability challenges associated with poorly soluble medications. The article highlights their transformative potential in pharmaceutical innovation, emphasizing the importance of continued research and optimization to harness their benefits effectively. Nanosuspensions offer a viable solution for enhancing drug solubility and bioavailability, with implications for improving therapeutic outcomes in various medical conditions.
{"title":"Nanosuspensions: Enhancing drug bioavailability through nanonization.","authors":"Rohit Chavhan","doi":"10.1016/j.pharma.2024.06.003","DOIUrl":"10.1016/j.pharma.2024.06.003","url":null,"abstract":"<p><strong>Introduction: </strong>Nanosuspensions have emerged as a promising avenue in pharmaceutical innovation, particularly for enhancing the bioavailability of poorly soluble medications. This article explores the transformative potential of nanosuspensions, emphasizing the critical role of particle size reduction through nanonization techniques. With conventional approaches often falling short in addressing the bioavailability challenges of hydrophobic drugs, nanosuspensions offer multifaceted applications and distinctive advantages in drug delivery.</p><p><strong>Methods: </strong>The study delves into various nanosuspension preparation techniques, including high-pressure homogenization, media milling, emulsification-solvent evaporation, precipitation, and supercritical fluid processes. Each method brings unique advantages and limitations, contributing to the expanding repertoire of nanosuspension formulation methods. The article emphasizes the necessity for meticulous planning, evaluation, and ongoing research across different drugs to optimize their use effectively.</p><p><strong>Results: </strong>Nanosuspensions exhibit versatility in administration routes, spanning parenteral, peroral, ocular, and pulmonary pathways, making them applicable across diverse dosage forms. Current efforts are directed towards furthering their application in site-specific medication administration, indicating their potential in tailored therapeutic strategies. Nanosuspensions offer a promising solution for enhancing drug solubility and bioavailability, addressing the persistent challenge of poor solubility in pharmaceutical compounds.</p><p><strong>Discussion: </strong>The significance of careful formulation and stabilization using polymers and surfactants is underscored, ensuring the efficacy and safety of nanosuspensions. By discussing the benefits, drawbacks, and nuances of each preparation technique, the article aims to simplify future research endeavors in the field of nanosuspensions. Additionally, a comprehensive overview of nanosuspensions, including their preparation methods, benefits, characterization, patents, marketed products, and intended uses, sheds light on this evolving domain in pharmaceutical sciences.</p><p><strong>Conclusion: </strong>Nanosuspensions represent a promising approach for overcoming bioavailability challenges associated with poorly soluble medications. The article highlights their transformative potential in pharmaceutical innovation, emphasizing the importance of continued research and optimization to harness their benefits effectively. Nanosuspensions offer a viable solution for enhancing drug solubility and bioavailability, with implications for improving therapeutic outcomes in various medical conditions.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141465868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-27DOI: 10.1016/j.pharma.2024.06.004
Wala Ammor, Christele Gras Le Guen, François Angoulvant, Sonia Prot-Labarthe
Medication errors are one of the causes of iatrogenic medication use in children. The POPI tool for detecting inappropriate drug prescriptions and prescription omissions in paediatrics was the first tool to be published in this field in 2014. Our aim was to update the POPI tool for French use based on current recommendations and practice. Criteria were removed, updated or added based on recommendations from learned societies and national bodies. The two-round Delphi method was used to reach a consensus of experts. The level of agreement of the healthcare professionals' proposals was rated on a 9-point Likert scale. In the first round, only proposals with a median agreement of 7 to 9 and an agreement of more than 65% were retained. In the second round, only those with a median agreement of 7 to 9 and over 75% agreement were retained. The POPI tool now includes eight categories (various, infectiology, gastroenterology, pneumonology, dermatology, neurology/pedopsychiatry, haematology and excipients). All the criteria were supported by bibliographical references. They were submitted to 20 French healthcare professionals: 9 pharmacists and 11 doctors (17 hospital-based and 3 self-employed). After two rounds of Delphi testing, 166 criteria were retained and validated (111 inappropriate prescriptions and 55 omissions). In conclusion, this study made it possible to update the POPI tool, which is still available for assessing paediatric prescriptions.
{"title":"[Consensus update of the POPI tool].","authors":"Wala Ammor, Christele Gras Le Guen, François Angoulvant, Sonia Prot-Labarthe","doi":"10.1016/j.pharma.2024.06.004","DOIUrl":"10.1016/j.pharma.2024.06.004","url":null,"abstract":"<p><p>Medication errors are one of the causes of iatrogenic medication use in children. The POPI tool for detecting inappropriate drug prescriptions and prescription omissions in paediatrics was the first tool to be published in this field in 2014. Our aim was to update the POPI tool for French use based on current recommendations and practice. Criteria were removed, updated or added based on recommendations from learned societies and national bodies. The two-round Delphi method was used to reach a consensus of experts. The level of agreement of the healthcare professionals' proposals was rated on a 9-point Likert scale. In the first round, only proposals with a median agreement of 7 to 9 and an agreement of more than 65% were retained. In the second round, only those with a median agreement of 7 to 9 and over 75% agreement were retained. The POPI tool now includes eight categories (various, infectiology, gastroenterology, pneumonology, dermatology, neurology/pedopsychiatry, haematology and excipients). All the criteria were supported by bibliographical references. They were submitted to 20 French healthcare professionals: 9 pharmacists and 11 doctors (17 hospital-based and 3 self-employed). After two rounds of Delphi testing, 166 criteria were retained and validated (111 inappropriate prescriptions and 55 omissions). In conclusion, this study made it possible to update the POPI tool, which is still available for assessing paediatric prescriptions.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141465866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-26DOI: 10.1016/j.pharma.2024.06.005
Dhrumi Patel, Sarika Wairkar
Objectives: Edaravone (EDR) is an effective neuroprotective agent in various neurological diseases; however, its use is restricted due to poor oral absorption. Bile salts are known for improving solubility and inhibiting drug crystallization in supersaturated conditions of the gastrointestinal tract (GIT). In our previous work, we prepared coamorphous dispersion (COAM) of EDR with sodium taurocholate (NaTC) using spray drying. The optimized EDR COAM exhibited superior in vitro performance compared to plain EDR. EDR is well absorbed in fasted-over-fed conditions.
Methods: The present work, we conducted a pharmacokinetic study for EDR and EDR COAM in fasted and fed conditions to check effect of food on its oral absorption. The LC-MS/MS-based method was developed and validated to determine the amount of EDR in plasma.
Results: The results suggested that EDR COAM did not show a significant difference in Cmax (P=0.3544) and AUC (P=0.1696) of fasted and fed states. On the other hand, plain EDR showed 2-fold and 3-fold reduced Cmax (P<0.0001) and AUC (P=0.0094) in the fed condition, respectively. The Cmax and AUC of EDR COAM were improved in fasted (AUC: 2.56-fold) and fed states (AUC: 5.74-fold) than plain EDR, suggesting better oral absorption of COAM than crystalline EDR without having the effect of food.
Conclusions: The unique structural attributes of NaTC had the potential to inhibit the recrystallization of EDR in GIT, while concurrently reducing the impact of food on the oral absorption of EDR.
{"title":"Effect of food on oral pharmacokinetics of edaravone coamorphous dispersion containing bile salts as coformers - Part II.","authors":"Dhrumi Patel, Sarika Wairkar","doi":"10.1016/j.pharma.2024.06.005","DOIUrl":"10.1016/j.pharma.2024.06.005","url":null,"abstract":"<p><strong>Objectives: </strong>Edaravone (EDR) is an effective neuroprotective agent in various neurological diseases; however, its use is restricted due to poor oral absorption. Bile salts are known for improving solubility and inhibiting drug crystallization in supersaturated conditions of the gastrointestinal tract (GIT). In our previous work, we prepared coamorphous dispersion (COAM) of EDR with sodium taurocholate (NaTC) using spray drying. The optimized EDR COAM exhibited superior in vitro performance compared to plain EDR. EDR is well absorbed in fasted-over-fed conditions.</p><p><strong>Methods: </strong>The present work, we conducted a pharmacokinetic study for EDR and EDR COAM in fasted and fed conditions to check effect of food on its oral absorption. The LC-MS/MS-based method was developed and validated to determine the amount of EDR in plasma.</p><p><strong>Results: </strong>The results suggested that EDR COAM did not show a significant difference in C<sub>max</sub> (P=0.3544) and AUC (P=0.1696) of fasted and fed states. On the other hand, plain EDR showed 2-fold and 3-fold reduced C<sub>max</sub> (P<0.0001) and AUC (P=0.0094) in the fed condition, respectively. The C<sub>max</sub> and AUC of EDR COAM were improved in fasted (AUC: 2.56-fold) and fed states (AUC: 5.74-fold) than plain EDR, suggesting better oral absorption of COAM than crystalline EDR without having the effect of food.</p><p><strong>Conclusions: </strong>The unique structural attributes of NaTC had the potential to inhibit the recrystallization of EDR in GIT, while concurrently reducing the impact of food on the oral absorption of EDR.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141465867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-11DOI: 10.1016/j.pharma.2024.06.001
Nida Sohail, Hafiza Farhat, Shamim Akhtar Qureshi, Irfan Ullah, Muhammad Shaiq Ali
Objectives: This study aimed to investigate the protective activity of brown seaweed, the ethanolic and water extracts of Sargassum binderi (S. binderi) were examined. Anticancer drug, cisplatin is normally used for the treatment of solid tumors that cause acute kidney damage after assemblage in the renal tubules.
Material and methods: It was an acute nephrotoxicity study, animals were divided into several groups randomly, cisplatin (7mg/kg i.p.) and normal saline were used as positive and negative control respectively. The S. bindari ethanolic and water extract were given orally in a dose of 200mg/kg for 5days. Various biomarkers were assessed to observe the nephroprotective potential, while antioxidant activities were investigated using reduced glutathione, catalase and malondialdehyde as oxidative stress. GCMS was performed to validate the presence of important therapeutic moieties.
Results: The current result justified that pretreatment with S. binderi inhibited the elevation of antioxidant parameters and also showed protection against lipid peroxidation, induced by cisplatin challenge. The overall impact was the nephroprotection, which has been revealed from the results. GCMS evaluation of hexanes fraction revealed the presence of therapeutically important compounds including heptasiloxane, 3,7,11,15-tetramethyl-2-hexadecen-1-ol, hexadecamethyl, cyclooctasiloxane, and hexadecamethyl. These compounds have been reported for their antioxidant, antibacterial, anticancer, and antifungal activities.
Conclusion: S. binderi showed reno-protective effect by checking their well-known biochemical parameters probably due to the antioxidant activity as confirmed by the presence of compounds.
{"title":"The brown algae: Sargassum binderi sonder bears potential nephroprotective activity in in-vivo experimental model.","authors":"Nida Sohail, Hafiza Farhat, Shamim Akhtar Qureshi, Irfan Ullah, Muhammad Shaiq Ali","doi":"10.1016/j.pharma.2024.06.001","DOIUrl":"10.1016/j.pharma.2024.06.001","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate the protective activity of brown seaweed, the ethanolic and water extracts of Sargassum binderi (S. binderi) were examined. Anticancer drug, cisplatin is normally used for the treatment of solid tumors that cause acute kidney damage after assemblage in the renal tubules.</p><p><strong>Material and methods: </strong>It was an acute nephrotoxicity study, animals were divided into several groups randomly, cisplatin (7mg/kg i.p.) and normal saline were used as positive and negative control respectively. The S. bindari ethanolic and water extract were given orally in a dose of 200mg/kg for 5days. Various biomarkers were assessed to observe the nephroprotective potential, while antioxidant activities were investigated using reduced glutathione, catalase and malondialdehyde as oxidative stress. GCMS was performed to validate the presence of important therapeutic moieties.</p><p><strong>Results: </strong>The current result justified that pretreatment with S. binderi inhibited the elevation of antioxidant parameters and also showed protection against lipid peroxidation, induced by cisplatin challenge. The overall impact was the nephroprotection, which has been revealed from the results. GCMS evaluation of hexanes fraction revealed the presence of therapeutically important compounds including heptasiloxane, 3,7,11,15-tetramethyl-2-hexadecen-1-ol, hexadecamethyl, cyclooctasiloxane, and hexadecamethyl. These compounds have been reported for their antioxidant, antibacterial, anticancer, and antifungal activities.</p><p><strong>Conclusion: </strong>S. binderi showed reno-protective effect by checking their well-known biochemical parameters probably due to the antioxidant activity as confirmed by the presence of compounds.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-01DOI: 10.1016/j.pharma.2024.02.006
Agung Giri Samudra , Agung Endro Nugroho , Retno Murwanti
Indonesia is the largest archipelagic country in the world, with 70% of its territory covered by oceans that are rich in various types of biological resources. Indonesia's biodiversity has made it possible to develop natural medicine. Marine algae have enormous potential, but the types of marine algae used still need to be more varied. Research on the pharmacology of marine macroalgae has been conducted in Indonesia, but studies on such topic related to diabetes mellitus (DM) still need to be completed. This study provides a comprehensive dataset of pharmacological anti-diabetic potential of marine macroalgae used for managing DM and reports on preclinical trials that provide pharmacological evidence. Data on the Indonesian marine macroalgae used to lower blood glucose were obtained from online sources. The bioactive chemicals of marine macroalgae have been found efficient at blocking several diabetes enzymes in in-vivo and in-vitro studies, and such chemicals have anti-inflammatory, anti-obesity, antioxidant, and other therapeutic benefits. The Google Scholar was used to search for the pharmacological literature with the keywords marine AND macroalgae AND diabetes AND Indonesia. Pharmacological research on the anti-diabetic activity of marine macroalgae has been carried out on five major Indonesian islands, including Sumatra, Kalimantan, Java, Sulawesi, and Papua, which encompassed 12 provinces: Southwest Papua, South Sulawesi, West Kalimantan, Riau Archipelago, Banten, West Java, North Sulawesi, East Java, Yogyakarta, Maluku, Jakarta, and Bengkulu. Articles on preclinical tests (in vitro and in vivo) were also used for the phytochemical problem section. The results briefly describe which class of algae has been widely used in Indonesia as an anti-diabetic. The findings of this research can be utilized to help find DM treatment drugs based on natural resources from marine macroalgae.
L’Indonésie est le plus grand pays archipélagique du monde, avec 70% de son territoire couvert par des océans riches en diverses ressources biologiques. La biodiversité indonésienne a permis de développer la médecine naturelle. Les algues marines ont un énorme potentiel, mais les types d’algues marines utilisées doivent encore être plus variés. Des recherches sur la pharmacologie des macroalgues marines ont été menées en Indonésie, mais des études sur des sujets liés au diabète sucré (DM) doivent encore être achevées. Cette étude fournit un ensemble de données complet sur le potentiel antidiabétique pharmacologique des macroalgues marines utilisées pour gérer la DM et des rapports sur des essais précliniques fournissant des preuves pharmacologiques. Les données sur les macroalgues marines indonésiennes utilisées pour abaisser la glycémie ont été obtenues à partir de sources en ligne. Les produits chimiques bioactifs des macroalgues marines se sont révélés efficaces pour bloquer plusieurs enzymes du diabète dans des études in vivo et in vitro
{"title":"Review of the pharmacological properties of marine macroalgae used in the treatment of diabetes mellitus in Indonesia","authors":"Agung Giri Samudra , Agung Endro Nugroho , Retno Murwanti","doi":"10.1016/j.pharma.2024.02.006","DOIUrl":"10.1016/j.pharma.2024.02.006","url":null,"abstract":"<div><p>Indonesia is the largest archipelagic country in the world, with 70% of its territory covered by oceans that are rich in various types of biological resources. Indonesia's biodiversity has made it possible to develop natural medicine. Marine algae have enormous potential, but the types of marine algae used still need to be more varied. Research on the pharmacology of marine macroalgae has been conducted in Indonesia, but studies on such topic related to diabetes mellitus (DM) still need to be completed. This study provides a comprehensive dataset of pharmacological anti-diabetic potential of marine macroalgae used for managing DM and reports on preclinical trials that provide pharmacological evidence. Data on the Indonesian marine macroalgae used to lower blood glucose were obtained from online sources. The bioactive chemicals of marine macroalgae have been found efficient at blocking several diabetes enzymes in in-vivo and in-vitro studies, and such chemicals have anti-inflammatory, anti-obesity, antioxidant, and other therapeutic benefits. The Google Scholar was used to search for the pharmacological literature with the keywords marine AND macroalgae AND diabetes AND Indonesia. Pharmacological research on the anti-diabetic activity of marine macroalgae has been carried out on five major Indonesian islands, including Sumatra, Kalimantan, Java, Sulawesi, and Papua, which encompassed 12 provinces: Southwest Papua, South Sulawesi, West Kalimantan, Riau Archipelago, Banten, West Java, North Sulawesi, East Java, Yogyakarta, Maluku, Jakarta, and Bengkulu. Articles on preclinical tests (in vitro and in vivo) were also used for the phytochemical problem section. The results briefly describe which class of algae has been widely used in Indonesia as an anti-diabetic. The findings of this research can be utilized to help find DM treatment drugs based on natural resources from marine macroalgae.</p></div><div><p>L’Indonésie est le plus grand pays archipélagique du monde, avec 70% de son territoire couvert par des océans riches en diverses ressources biologiques. La biodiversité indonésienne a permis de développer la médecine naturelle. Les algues marines ont un énorme potentiel, mais les types d’algues marines utilisées doivent encore être plus variés. Des recherches sur la pharmacologie des macroalgues marines ont été menées en Indonésie, mais des études sur des sujets liés au diabète sucré (DM) doivent encore être achevées. Cette étude fournit un ensemble de données complet sur le potentiel antidiabétique pharmacologique des macroalgues marines utilisées pour gérer la DM et des rapports sur des essais précliniques fournissant des preuves pharmacologiques. Les données sur les macroalgues marines indonésiennes utilisées pour abaisser la glycémie ont été obtenues à partir de sources en ligne. Les produits chimiques bioactifs des macroalgues marines se sont révélés efficaces pour bloquer plusieurs enzymes du diabète dans des études in vivo et in vitro","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139734293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The expenses of multiple myeloma (MM) represent a real economic and societal burden for patients and health authorities. However, very little is known about the situation in Algeria. Therefore, the aim of this study is to evaluate the costs generated by the management of MM and its complications in Algerian patients.
Materials and methods
An observational retrospective study conducted on patients diagnosed with MM, from January 1st, 2019 to April 31st, 2023, at the Establishment Hospitalier Universitaire November 1st, Oran. A bottom-up costing methodology was used to assess the phase-specific cost and the complication burden.
Results
In total, 249 qualified for the study. For autologous stem cell transplantation (ASCT) eligible patients, the mean per patient cost of treating myeloma was estimated at: induction regimen ($4072); ASCT ($2899); consolidation ($1538); and maintenance ($355.76). The mean drug cost for ASCT-ineligible patients was $1421. The use of generic bortezomib and generic melphalan has led to a reduction in expenses of $1,075,181 ($5,024 per patient; 55.35%) and $10,864 ($487 per patient; 15.07%), respectively. Another cost-saving adaptation was ASCT using non-cryopreserved (NC) stem cells. The cost of managing MM complications was $177,782 per year.
Conclusion
A number of adjustments have been implemented to the management of MM over time to improve clinical efficacy and reduce costs in Algeria. However, this may have come with a startlingly high cost of complications.
Contexte
Les dépenses liées au myélome multiple (MM) représentent un véritable fardeau économique et sociétal pour les patients et les autorités sanitaires. Cependant, la situation en Algérie est très peu connue. L’objectif de cette étude est donc d’évaluer les coûts générés par la prise en charge du MM et de ses complications chez les patients algériens.
Matériels et méthodes
Une étude rétrospective observationnelle menée sur des patients diagnostiqués avec un MM, du 1er janvier 2019 au 31 avril 2023, à l’établissement hospitalier universitaire du 1er novembre, Oran. Une méthodologie de calcul des coûts ascendants a été utilisée pour évaluer le coût spécifique à la phase et des complications.
Résultats
Au total, 249 personnes se sont qualifiées pour l’étude. Pour les patients éligibles à une autogreffe de cellules souches (ASCT), le coût moyen par patient du traitement du myélome a été estimé à : régime d’induction (4072 $) ; ASCT (2899 $) ; consolidation (1538 $) ; et maintenance (356 $). Le coût moyen des médicaments pour les patients non éligibles à l’ASCT était de 1421 $. L’utilisation de bortezomib générique et de melphalan générique a entraîné une réduction des dépenses de 1 075 181 $ (5024 $ par patient ; 55,35 %) et de 10 864 $ (487,10 $ par patient ; 15,07 %)
{"title":"The cost of multiple myeloma and its complications: A single-center study from Oran, Algeria","authors":"Fairouz Haouatti , Ikram K. Belhadj , Ahlem Goumidi , Nabil Yafour , Houari Toumi","doi":"10.1016/j.pharma.2024.02.001","DOIUrl":"10.1016/j.pharma.2024.02.001","url":null,"abstract":"<div><h3>Background</h3><p>The expenses of multiple myeloma (MM) represent a real economic and societal burden for patients and health authorities. However, very little is known about the situation in Algeria. Therefore, the aim of this study is to evaluate the costs generated by the management of MM and its complications in Algerian patients.</p></div><div><h3>Materials and methods</h3><p>An observational retrospective study conducted on patients diagnosed with MM, from January 1st, 2019 to April 31st, 2023, at the Establishment Hospitalier Universitaire November 1st, Oran. A bottom-up costing methodology was used to assess the phase-specific cost and the complication burden.</p></div><div><h3>Results</h3><p>In total, 249 qualified for the study. For autologous stem cell transplantation (ASCT) eligible patients, the mean per patient cost of treating myeloma was estimated at: induction regimen ($4072); ASCT ($2899); consolidation ($1538); and maintenance ($355.76). The mean drug cost for ASCT-ineligible patients was $1421. The use of generic bortezomib and generic melphalan has led to a reduction in expenses of $1,075,181 ($5,024 per patient; 55.35%) and $10,864 ($487 per patient; 15.07%), respectively. Another cost-saving adaptation was ASCT using non-cryopreserved (NC) stem cells. The cost of managing MM complications was $177,782 per year.</p></div><div><h3>Conclusion</h3><p>A number of adjustments have been implemented to the management of MM over time to improve clinical efficacy and reduce costs in Algeria. However, this may have come with a startlingly high cost of complications.</p></div><div><h3>Contexte</h3><p>Les dépenses liées au myélome multiple (MM) représentent un véritable fardeau économique et sociétal pour les patients et les autorités sanitaires. Cependant, la situation en Algérie est très peu connue. L’objectif de cette étude est donc d’évaluer les coûts générés par la prise en charge du MM et de ses complications chez les patients algériens.</p></div><div><h3>Matériels et méthodes</h3><p>Une étude rétrospective observationnelle menée sur des patients diagnostiqués avec un MM, du 1<sup>er</sup> janvier 2019 au 31 avril 2023, à l’établissement hospitalier universitaire du 1<sup>er</sup> novembre, Oran. Une méthodologie de calcul des coûts ascendants a été utilisée pour évaluer le coût spécifique à la phase et des complications.</p></div><div><h3>Résultats</h3><p>Au total, 249 personnes se sont qualifiées pour l’étude. Pour les patients éligibles à une autogreffe de cellules souches (ASCT), le coût moyen par patient du traitement du myélome a été estimé à : régime d’induction (4072 $) ; ASCT (2899 $) ; consolidation (1538 $) ; et maintenance (356 $). Le coût moyen des médicaments pour les patients non éligibles à l’ASCT était de 1421 $. L’utilisation de bortezomib générique et de melphalan générique a entraîné une réduction des dépenses de 1 075 181 $ (5024 $ par patient ; 55,35 %) et de 10 864 $ (487,10 $ par patient ; 15,07 %)","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139715762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-01DOI: 10.1016/j.pharma.2024.02.015
Jeanice Amiot , Marie Hélène Bruge Ansel , Mathilde Bruyas , Marc Rinaudo , Emilie Rulliat , Jérôme Gauthier , Vincent Piriou , Delphine Cabelguenne
Introduction
In anesthesia, a medication error would occur every 20 to 133 anesthesia procedures, and 14% is related to a route administration error. To secure neuraxial route, ISO group published a norm in 2016 to develop specific connectors, the “NRFit® connector”. The main objective of this work, is to develop a risk mapping related to neuraxial medication errors therefore prepare the NRFit® implementation in anesthesia units in a French Universitary Hospital.
Methods
Failure modes, effects and criticality analysis (FMECA) methodology was used for our risk mapping which was divided in 3 anesthesia specialities. For each, the analysis was performed for accidental neuraxial administration of intravenous drugs, and its opposite error. Secondly, NRFit® devices were tested for 1 month by 3 experimented anesthetists.
Results
The majority of reported errors concerns epidural and intrathecal anesthesia, and more frequently in the field of obstetrics. Opioids and tranexamic acid, administered in neuraxial route, are drugs with the highest criticality. The tests were rather conclusive and made it possible to highlight the additional needs in medical devices.
Discussion
Obstetrics is the riskiest area due to the frequency of epidural anesthesia, the administration of critical drugs in intravenous and neuraxial route. This work increased the awareness of our group, improved the measure of this risk and harmonized practices.
Conclusion
This work is the first step of the project to prevent administration route error in anesthesia during patient's drug management. The next step will be the NRFit® implementation for epidural and combined spinal-epidural anesthesia in our hospital.
Introduction
En Anesthésie, une erreur médicamenteuse surviendrait toutes les 20 à 133 procédures, et 14 % sont liées à une erreur de voie d’administration. Pour sécuriser la voie neuraxiale, la norme ISO 80369-6 propose une connectique dédiée, la connectique « NRFit® ». Le principal objectif de ce travail est de réaliser une cartographie des risques concernant les erreurs médicamenteuses en lien avec cette voie, afin de préparer la transition à la connectique NRFit® en Anesthésie.
Méthodologie
La méthodologie Analyse des modes de défaillance, de leurs effets et de leur criticité (AMDEC) a été utilisée. Il a été analysé les administrations accidentelles neuraxiales de médicaments destinés à la voie intraveineuse, ainsi que l’erreur opposée. Puis, les dispositifs médicaux NRFit® ont été testés pendant 1 mois par 3 anesthésistes expérimentés.
Résultats
La majorité des erreurs publiées concernent l’anesthésie péridurale et intrathécale, et plus fréquemment dans le domaine de l’obstétrique. Les opioïdes et l’acide tranexamique, administrés par voie neuraxiale, sont les médicaments les plus critiques
{"title":"Strategy to secure the neuraxial route in anaesthesia: Risk mapping and feedback from the application of the ISO 80369-6 standard NRFit® connectors","authors":"Jeanice Amiot , Marie Hélène Bruge Ansel , Mathilde Bruyas , Marc Rinaudo , Emilie Rulliat , Jérôme Gauthier , Vincent Piriou , Delphine Cabelguenne","doi":"10.1016/j.pharma.2024.02.015","DOIUrl":"10.1016/j.pharma.2024.02.015","url":null,"abstract":"<div><h3>Introduction</h3><p>In anesthesia, a medication error would occur every 20 to 133 anesthesia procedures, and 14% is related to a route administration error. To secure neuraxial route, ISO group published a norm in 2016 to develop specific connectors, the “NRFit® connector”. The main objective of this work, is to develop a risk mapping related to neuraxial medication errors therefore prepare the NRFit® implementation in anesthesia units in a French Universitary Hospital.</p></div><div><h3>Methods</h3><p>Failure modes, effects and criticality analysis (FMECA) methodology was used for our risk mapping which was divided in 3 anesthesia specialities. For each, the analysis was performed for accidental neuraxial administration of intravenous drugs, and its opposite error. Secondly, NRFit® devices were tested for 1 month by 3 experimented anesthetists.</p></div><div><h3>Results</h3><p>The majority of reported errors concerns epidural and intrathecal anesthesia, and more frequently in the field of obstetrics. Opioids and tranexamic acid, administered in neuraxial route, are drugs with the highest criticality. The tests were rather conclusive and made it possible to highlight the additional needs in medical devices.</p></div><div><h3>Discussion</h3><p>Obstetrics is the riskiest area due to the frequency of epidural anesthesia, the administration of critical drugs in intravenous and neuraxial route. This work increased the awareness of our group, improved the measure of this risk and harmonized practices.</p></div><div><h3>Conclusion</h3><p>This work is the first step of the project to prevent administration route error in anesthesia during patient's drug management. The next step will be the NRFit® implementation for epidural and combined spinal-epidural anesthesia in our hospital.</p></div><div><h3>Introduction</h3><p>En Anesthésie, une erreur médicamenteuse surviendrait toutes les 20 à 133 procédures, et 14 % sont liées à une erreur de voie d’administration. Pour sécuriser la voie neuraxiale, la norme ISO 80369-6 propose une connectique dédiée, la connectique « NRFit® ». Le principal objectif de ce travail est de réaliser une cartographie des risques concernant les erreurs médicamenteuses en lien avec cette voie, afin de préparer la transition à la connectique NRFit® en Anesthésie.</p></div><div><h3>Méthodologie</h3><p>La méthodologie Analyse des modes de défaillance, de leurs effets et de leur criticité (AMDEC) a été utilisée. Il a été analysé les administrations accidentelles neuraxiales de médicaments destinés à la voie intraveineuse, ainsi que l’erreur opposée. Puis, les dispositifs médicaux NRFit® ont été testés pendant 1 mois par 3 anesthésistes expérimentés.</p></div><div><h3>Résultats</h3><p>La majorité des erreurs publiées concernent l’anesthésie péridurale et intrathécale, et plus fréquemment dans le domaine de l’obstétrique. Les opioïdes et l’acide tranexamique, administrés par voie neuraxiale, sont les médicaments les plus critiques","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140048664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Satureja kermanica is a native species with a relatively wide distribution in Iran, which has been studied less. Due to the low stability of the plants, in this study, the methanolic extract of S. kermanica (MSK) along with a nanoemulsion (NEK) preparation was evaluated in terms of antioxidant and cytotoxic activity.
Material and methods
The aerial parts of S. kermanica were collected and after studying the organoleptic characteristics and quality control parameters, were extracted with methanol. Total phenolic compounds and total flavonoids of the plant were measured. A nanoemulsion preparation was prepared using ultrasonication method from S. kermanica extract. After measuring the particle size of nanoemulsion, both MSK and NEK were evaluated for their antioxidant and cytotoxic activity using DPPH scavenging assay and MTT colorimetric method on breast cancer cell line (MCF-7) respectively.
Results
Phytochemical studies exhibited the presence of secondary metabolites including flavonoids, tannins, steroids and carbohydrates in the plant. Based on the histogram of the SBL nanosizer, the average diameter of nanoemulsion was determined as 37.09 nm. Both MSK and NEK showed dose-dependent antioxidant and cytotoxic activity. The IC50 value of MSK and NEK for DPPH inhibition was 30.105 ± 2.781 58.14 ± 0.84 μg/mL and for toxicity toward MCF-7 cell line was 1251.088 and 201.745 ± 4.554 μg/mL respectively.
Conclusion
MSK and NEK showed antioxidant and cytotoxic activity, but in NEK, the antioxidant and cytotoxic potential of the plant was more prominent, which may be due to the rapid release of the bioactive component from the nanoemulsion.
Objectif
Satureja kermanica est une espèce indigène avec une répartition relativement large en Iran, qui a été moins étudiée. En raison de la faible stabilité des plantes, dans cette étude, l’extrait méthanolique de S. kermanica (MSK) ainsi qu’une préparation de nanoémulsion (NEK) ont été évalués en termes d’activité antioxydante et cytotoxique.
Matériel et méthodes
Les parties aériennes de S. kermanica ont été collectées et après étude des caractéristiques organoleptiques et des paramètres de contrôle qualité, ont été extraites au méthanol. Les composés phénoliques totaux et les flavonoïdes totaux de la plante ont été mesurés. Une préparation de nanoémulsion a été préparée en utilisant la méthode de sonication à partir d’un extrait de S. kermanica. Après avoir mesuré la taille des particules de la nanoémulsion, MSK et NEK ont été évalués pour leur activité antioxydante et cytotoxique à l’aide du test de piégeage DPPH et de la méthode colorimétrique MTT sur la lignée cellulaire du cancer du sein (MCF-
目的:Satureja kermanica 是一种原生植物,在伊朗分布较广,但研究较少。由于植物的稳定性较低,本研究对 S. kermanica 的甲醇提取物(MSK)和纳米乳液(NEK)制剂的抗氧化性和细胞毒性活性进行了评估:材料和方法:采集 S. kermanica 的气生部分,研究其感官特征和质量控制参数后,用甲醇提取。测定了植物的总酚类化合物和总黄酮类化合物。用超声波法从 S. kermanica 提取物中制备纳米乳液。测量纳米乳液的粒度后,分别使用 DPPH 清除法和 MTT 比色法对 MSK 和 NEK 在乳腺癌细胞系(MCF- 7)上的抗氧化性和细胞毒性活性进行了评估:植物化学研究表明,该植物中含有黄酮类、单宁酸、类固醇和碳水化合物等次生代谢物。根据 SBL 纳米粒度仪的直方图,确定纳米乳液的平均直径为 37.09 nm。MSK 和 NEK 都表现出剂量依赖性的抗氧化和细胞毒性活性。MSK 和 NEK 抑制 DPPH 的 IC50 值分别为 30.105 ± 2.781 58.14 ± 0.84μg/ml ,对 MCF-7 细胞株的毒性分别为 1251.088 和 201.745 ± 4.554 µg/ml:MSK和NEK具有抗氧化和细胞毒性活性,但在NEK中,植物的抗氧化和细胞毒性潜力更为突出,这可能是由于生物活性成分从纳米乳液中快速释放所致。
{"title":"Antioxidant and cytotoxicity activity of a nanoemulsion from Satureja kermanica (Lamiaceae)","authors":"Navid Hassanabadi , Zahra Mahdavi Meymand , Anis Ashrafzadeh , Fariba Sharififar","doi":"10.1016/j.pharma.2024.01.005","DOIUrl":"10.1016/j.pharma.2024.01.005","url":null,"abstract":"<div><h3>Objective</h3><p><em>Satureja kermanica</em> is a native species with a relatively wide distribution in Iran, which has been studied less. Due to the low stability of the plants, in this study, the methanolic extract of <em>S. kermanica</em> (MSK) along with a nanoemulsion (NEK) preparation was evaluated in terms of antioxidant and cytotoxic activity.</p></div><div><h3>Material and methods</h3><p>The aerial parts of <em>S. kermanica</em> were collected and after studying the organoleptic characteristics and quality control parameters, were extracted with methanol. Total phenolic compounds and total flavonoids of the plant were measured. A nanoemulsion preparation was prepared using ultrasonication method from <em>S. kermanica</em> extract. After measuring the particle size of nanoemulsion, both MSK and NEK were evaluated for their antioxidant and cytotoxic activity using DPPH scavenging assay and MTT colorimetric method on breast cancer cell line (MCF-7) respectively.</p></div><div><h3>Results</h3><p>Phytochemical studies exhibited the presence of secondary metabolites including flavonoids, tannins, steroids and carbohydrates in the plant. Based on the histogram of the SBL nanosizer, the average diameter of nanoemulsion was determined as 37.09<!--> <!-->nm. Both MSK and NEK showed dose-dependent antioxidant and cytotoxic activity. The IC<sub>50</sub> value of MSK and NEK for DPPH inhibition was 30.105<!--> <!-->±<!--> <!-->2.781 58.14<!--> <!-->±<!--> <!-->0.84<!--> <!-->μg/mL and for toxicity toward MCF-7 cell line was 1251.088 and 201.745<!--> <!-->±<!--> <!-->4.554<!--> <!-->μg/mL respectively.</p></div><div><h3>Conclusion</h3><p>MSK and NEK showed antioxidant and cytotoxic activity, but in NEK, the antioxidant and cytotoxic potential of the plant was more prominent, which may be due to the rapid release of the bioactive component from the nanoemulsion.</p></div><div><h3>Objectif</h3><p><em>Satureja kermanica</em> est une espèce indigène avec une répartition relativement large en Iran, qui a été moins étudiée. En raison de la faible stabilité des plantes, dans cette étude, l’extrait méthanolique de <em>S. kermanica</em> (MSK) ainsi qu’une préparation de nanoémulsion (NEK) ont été évalués en termes d’activité antioxydante et cytotoxique.</p></div><div><h3>Matériel et méthodes</h3><p>Les parties aériennes de <em>S. kermanica</em> ont été collectées et après étude des caractéristiques organoleptiques et des paramètres de contrôle qualité, ont été extraites au méthanol. Les composés phénoliques totaux et les flavonoïdes totaux de la plante ont été mesurés. Une préparation de nanoémulsion a été préparée en utilisant la méthode de sonication à partir d’un extrait de <em>S. kermanica</em>. Après avoir mesuré la taille des particules de la nanoémulsion, MSK et NEK ont été évalués pour leur activité antioxydante et cytotoxique à l’aide du test de piégeage DPPH et de la méthode colorimétrique MTT sur la lignée cellulaire du cancer du sein (MCF-","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139569702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}